Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. A total of 250 patients treated with E or AA in 5 centers were included. The...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/2f1961a10d9b47f5b41b353c34cd4036 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!